I agree Novartis may be waiting from clearer pathway from FDA. Also we can not rule out the possibility that they are also very interested in progressing Rexlemestrocel for CHF (concurrently with Remestemcel for ARDS). This scenario would also require further guidance from the FDA and would also require further negotiations with MSB (which would explain the wait).
I agree Novartis may be waiting from clearer pathway from FDA....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.045(4.37%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $4.842M | 4.534M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 43495 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 36068 | 20 |
View Market Depth
| Last trade - 15.02pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |